A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 250 mg lebrikizumab in patients with localized scleroderma (LEMO)
Matching placebo to IMPEbglyss 250 mg solution for injection in pre-filled syringe
Eligibility
Age group
18-64 years, 65+ years
Sex
Female, Male
Primary endpoint
mLoSSI score after 24 weeks. Absolute change from baseline visit in mLoSSI score will be compared between groups
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.